PMID- 33587940
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 330
DP  - 2021 May 1
TI  - Combining sodium-glucose cotransporter 2 inhibitors and angiotensin 
      receptor-neprilysin inhibitors in heart failure patients with reduced ejection 
      fraction and diabetes mellitus: A multi-institutional study.
PG  - 91-97
LID - S0167-5273(21)00288-6 [pii]
LID - 10.1016/j.ijcard.2021.02.035 [doi]
AB  - BACKGROUND: Few studies investigated the combination of sodium-glucose 
      cotransporter 2 inhibitors (SGLT2is) and angiotensin receptor-neprilysin 
      inhibitors (ARNIs) in patients with heart failure with reduced ejection fraction 
      (HFrEF) and type 2 diabetes mellitus (T2DM). METHODS: During 2016 to 2018, 
      patients with HFrEF and T2DM were identified from Chang Gung Research Database; a 
      database deriving from the original electronic medical records of 7 hospitals in 
      Taiwan. They were classified into four subgroups according to the medications 
      received as follows: 1) SGLT2i and ARNI; 2) SGLT2i and no ARNI; 3) ARNI and no 
      SGLT2i; and 4) no SGLT2i and no ARNI. We examined clinical and safety 
      (hyperkalemia and acute renal dysfunction) outcomes over 1-year of follow-up. 
      RESULTS: A total of 2312 patients were eligible for analysis, including 169, 285, 
      338, and 1520 in subgroups 1, 2, 3 and 4, respectively. There were large 
      differences in baseline characteristics and treatments among subgroups. Subgroup 
      1 had the lowest rates of HF hospitalizations, all-cause death, and the composite 
      of both, and subgroup 4 had the highest event rates. A similar pattern was 
      observed for the safety outcomes. These differences were attenuated after 
      adjusting for differences in baseline variables and therapy. CONCLUSIONS: 
      Treatment with a combination of SGLT2i and ARNI was well tolerated in diabetic 
      patients with HFrEF and was associated with lower risk of heart failure 
      hospitalization.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Hsiao, Fu-Chih
AU  - Hsiao FC
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
FAU - Lin, Chia-Pin
AU  - Lin CP
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
FAU - Tung, Ying-Chang
AU  - Tung YC
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
FAU - Chang, Po-Cheng
AU  - Chang PC
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
FAU - McMurray, John J V
AU  - McMurray JJV
AD  - BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical 
      Sciences, University of Glasgow, Glasgow, United Kingdom.
FAU - Chu, Pao-Hsien
AU  - Chu PH
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Taipei, Taiwan. Electronic 
      address: taipei.chu@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20210213
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Receptors, Angiotensin)
RN  - 9NEZ333N27 (Sodium)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy/epidemiology
MH  - Glucose
MH  - *Heart Failure/diagnosis/drug therapy
MH  - Humans
MH  - Neprilysin
MH  - Receptors, Angiotensin
MH  - Sodium
MH  - Stroke Volume
MH  - Taiwan/epidemiology
OTO - NOTNLM
OT  - Angiotensin receptor-neprilysin inhibitors
OT  - Heart failure with reduced ejection fraction
OT  - Sodium-glucose cotransporter 2 inhibitors
OT  - Type 2 diabetes mellitus
EDAT- 2021/02/16 06:00
MHDA- 2021/05/29 06:00
CRDT- 2021/02/15 20:09
PHST- 2020/11/29 00:00 [received]
PHST- 2021/01/13 00:00 [revised]
PHST- 2021/02/11 00:00 [accepted]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
PHST- 2021/02/15 20:09 [entrez]
AID - S0167-5273(21)00288-6 [pii]
AID - 10.1016/j.ijcard.2021.02.035 [doi]
PST - ppublish
SO  - Int J Cardiol. 2021 May 1;330:91-97. doi: 10.1016/j.ijcard.2021.02.035. Epub 2021 
      Feb 13.